Drug reference
Rucaparib is a PARP inhibitor. PARP are enzymes that repair damaged DNA in cancer cells and, in the absence of functional BRCA, inhibition of PARP results in an inability of cancer cells to repair. Therefore inhibition of PARP results in an antineoplastic effect.
PDF page 1086
Ovarian cancer (initiated by a specialist) | Fallopian tube cancer (initiated by a specialist) | Peritoneal cancer (initiated by a specialist) ▶BY MOUTH ▶Adult: 600 mg twice daily, for dose adjustments due to side-effects—consult product literature
PDF page 1086
NICE decisions ▶Rucaparib for maintenance treatment of relapsed platinum- sensitive ovarian, fallopian tube or peritoneal cancer (November 2019) NICE TA611 Rucaparib (Rubraca ®) is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement are followed. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/ta611 Scottish Medicines Consortium (SMC) decisions SMC No. SMC2224 The Scottish Medicines Consortium has advised (March 2020) that rucaparib (Rubraca ®) is accepted for restricted use within NHS Scotland as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. It is restricted to those patients who do not have a BRCA mutation. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
PDF page 1087
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.
PDF page 1086
→Appendix 1: rucaparib
PDF page 1086
▶Common or very common Anaemia. appetite decreased. asthenia. decreased leucocytes. diarrhoea. dizziness. dyspepsia. dyspnoea. fever. hypercholesterolaemia. nausea. neutropenia. photosensitivity reaction. skin reactions. taste altered. thrombocytopenia. vomiting ▶Uncommon Acute myeloid leukaemia (discontinue). myelodysplastic syndrome (discontinue) ▶Frequency not known Memory loss
PDF page 1086
Manufacturer advises effective contraception in women of childbearing potential during treatment and for 6 months after receiving the last dose.
PDF page 1086
Manufacturer advises avoid—toxicity in animal studies.
PDF page 1086
Manufacturer advises avoid during treatment and for 2 weeks after last dose—no information available.
PDF page 1086
Manufacturer advises avoid in moderate to severe impairment (limited information available).
PDF page 1086
Manufacturer advises avoid in severe impairment unless benefit outweighs potential risk—no information available.
PDF page 1086
Manufacturer advises monitor full blood count before treatment initiation, then monthly thereafter.
PDF page 1086
There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Rubraca (Clovis Oncology UK Ltd) A Rucaparib (as Rucaparib camsilate) 200 mg Rubraca 200mg tablets | 60 tablet P s Rucaparib (as Rucaparib camsilate) 250 mg Rubraca 250mg tablets | 60 tablet P s Rucaparib (as Rucaparib camsilate) 300 mg Rubraca 300mg tablets | 60 tablet P s
PDF page 1087
Driving and skilled tasks Manufacturer advises patients and their carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness and fatigue.
PDF page 1087
600 mg twice daily, for dose adjustments due to
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1086
